Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE(2) in colorectal cancer

por Cebola, Inês, Custodio, Joaquin, Muñoz, Mar, Díez-Villanueva, Anna, Paré, Laia, Prieto, Patricia, Aussó, Susanna, Coll-Mulet, Llorenç, Boscá, Lisardo, Moreno, Victor, Peinado, Miguel A.
Publicado 2015

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

por Prat, Aleix, Chaudhury, Anwesha, Solovieff, Nadia, Paré, Laia, Martinez, Débora, Chic, Nuria, Martínez-Sáez, Olga, Brasó-Maristany, Fara, Lteif, Agnes, Taran, Tetiana, Babbar, Naveen, Su, Fei
Publicado 2021

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

por Buus, Richard, Szijgyarto, Zsolt, Schuster, Eugene F., Xiao, Hui, Haynes, Ben P., Sestak, Ivana, Cuzick, Jack, Paré, Laia, Seguí, Elia, Chic, Nuria, Prat, Aleix, Dowsett, Mitch, Cheang, Maggie Chon U.
Publicado 2021

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

por Prat, Aleix, Fan, Cheng, Fernández, Aranzazu, Hoadley, Katherine A., Martinello, Rossella, Vidal, Maria, Viladot, Margarita, Pineda, Estela, Arance, Ana, Muñoz, Montserrat, Paré, Laia, Cheang, Maggie C. U., Adamo, Barbara, Perou, Charles M.
Publicado 2015

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

por Griguolo, Gaia, Dieci, Maria Vittoria, Paré, Laia, Miglietta, Federica, Generali, Daniele Giulio, Frassoldati, Antonio, Cavanna, Luigi, Bisagni, Giancarlo, Piacentini, Federico, Tagliafico, Enrico, Cagossi, Katia, Ficarra, Guido, Prat, Aleix, Conte, Pierfranco, Guarneri, Valentina
Publicado 2021

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

por Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix
Publicado 2019

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single...

por Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix
Publicado 2019

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

por Isola, Ignacio, Brasó-Maristany, Fara, Moreno, David F., Mena, Mari-Pau, Oliver-Calders, Aina, Paré, Laia, Rodríguez-Lobato, Luis Gerardo, Martin-Antonio, Beatriz, Cibeira, María Teresa, Bladé, Joan, Rosiñol, Laura, Prat, Aleix, Lozano, Ester, Fernández de Larrea, Carlos
Publicado 2021

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

por Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix
Publicado 2019

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

por Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, Cortés, Javier
Publicado 2021

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

por Guarneri, Valentina, Brasó-Maristany, Fara, Dieci, Maria Vittoria, Griguolo, Gaia, Paré, Laia, Marín-Aguilera, Mercedes, Miglietta, Federica, Bottosso, Michele, Giorgi, Carlo Alberto, Blasco, Paula, Castillo, Oleguer, Galván, Patricia, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., Conte, PierFranco, Prat, Aleix
Publicado 2022

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt...

por Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix
Publicado 2019

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

por Pernas, Sonia, Villagrasa, Patricia, Vivancos, Ana, Scaltriti, Maurizio, Rodón, Jordi, Burgués, Octavio, Nuciforo, Paolo, Canes, Jordi, Paré, Laia, Dueñas, Marta, Vidal, Maria, Cejalvo, Juan Miguel, Perelló, Antonia, Llommbard-Cussac, Antonio, Dorca, Joan, Montaño, Alvaro, Pascual, Tomás, Oliveira, Mafalda, Ribas, Gloria, Rapado, Inmaculada, Prat, Aleix, Ciruelos, Eva
Publicado 2021

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

por De Mattos-Arruda, Leticia, Cortes, Javier, Blanco-Heredia, Juan, Tiezzi, Daniel G., Villacampa, Guillermo, Gonçalves-Ribeiro, Samuel, Paré, Laia, Souza, Carla Anjos, Ortega, Vanesa, Sammut, Stephen-John, Cusco, Pol, Fasani, Roberta, Chin, Suet-Feung, Perez-Garcia, Jose, Dienstmann, Rodrigo, Nuciforo, Paolo, Villagrasa, Patricia, Rubio, Isabel T., Prat, Aleix, Caldas, Carlos
Publicado 2021

Gene expression profiles of breast cancer metastasis according to organ site

por Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix
Publicado 2021

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analy...

por Fernandez-Martinez, Aranzazu, Pascual, Tomás, Singh, Baljit, Nuciforo, Paolo, Rashid, Naim U., Ballman, Karla V., Campbell, Jordan D., Hoadley, Katherine A., Spears, Patricia A., Pare, Laia, Brasó-Maristany, Fara, Chic, Nuria, Krop, Ian, Partridge, Ann, Cortés, Javier, Llombart-Cussac, Antonio, Prat, Aleix, Perou, Charles M., Carey, Lisa A.
Publicado 2023

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

por Gómez-Miragaya, Jorge, Palafox, Marta, Paré, Laia, Yoldi, Guillermo, Ferrer, Irene, Vila, Sergi, Galván, Patricia, Pellegrini, Pasquale, Pérez-Montoyo, Hector, Igea, Ana, Muñoz, Purificación, Esteller, Manel, Nebreda, Angel R., Urruticoechea, Ander, Morilla, Idoia, Pernas, Sonia, Climent, Fina, Soler-Monso, María Teresa, Petit, Ana, Serra, Violeta, Prat, Aleix, González-Suárez, Eva
Publicado 2017

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

por Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix
Publicado 2019

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

por Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix
Publicado 2020

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

por Garrido-Castro, Ana C., Saura, Cristina, Barroso-Sousa, Romualdo, Guo, Hao, Ciruelos, Eva, Bermejo, Begoña, Gavilá, Joaquin, Serra, Violeta, Prat, Aleix, Paré, Laia, Céliz, Pamela, Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L., Krop, Ian E., Solit, David B., Mills, Gordon B., Cantley, Lewis C., Winer, Eric P., Lin, Nancy U., Rodon, Jordi
Publicado 2020